Bringing synthetic biology to transcriptional regulation could catalyse a new generation of gene therapies that are more tunable, disease-specific and easy to deliver than the products dominating the field. In a recent article for BioCentury Innovations, Karen Tkach Tuzman spoke to Dr Michael Roberts, CSO of Synpromics, about synthetic promoters and how Synpromics is using combinations of natural gene sequences to guide gene expression.
Artificial Intelligence is a hot topic of conversation in pretty much every industry all the way from manufacturing to education. Biotech is no exception and given the sheer amount of genomic data being produced AI is becoming an integral part of gene therapy research. This could lead to greater precision in gene editing and ultimately more personalised treatments in the future. Dr Michael Roberts, CSO of Synpromics, spoke to Daniel Allen about the role AI can play in genomic medicine and the ways Synpromics is already utilising it.
The past decade has seen a resurgence in the field of cell and gene therapy, with three treatments being approved by the European Medicines Agency and the US Food and Drug Administration and a flood of candidate therapies nearing the end of Phase 3 clinical trials, a number of which are demonstrating promising results.
Read the full article published by MedNous – download PDF.
The research and development agreement will develop synthetic promoters for use in immune system cells including lymphoid, myeloid and microglia cells.
Synpromics announces the appointment of Sarah Haecker Meeks, PhD to the position of Vice President, Business Development.